Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Xencor, Inc.
With
ICON plc
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed well differentiated low or intermediate grade (World Health Organization \[WHO\] Grade 1 or 2) NET of pancreatic, gastrointestinal, lung, or undetermined origin that is locally advanced or metastatic and has progressed within the past 12 months
Histologically confirmed GIST that is locally advanced or metastatic
NET and GIST tumors must be unresectable
NET subjects must have progressed on or been ineligible for treatment with somatostatin analogues (SSA) and at least one other FDA-approved targeted therapy (everolimus or sunitinib).
GIST subjects must have previously received all FDA-approved therapies (imatinib mesylate, sunitinib malate, and regorafenib) for which they are eligible
Must have disease measurable by RECIST 1.1 criteria using either computed tomography (CT) or magnetic resonance imaging (MRI) scan
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You may not be if
Diagnosis of high-grade (WHO Grade 3) or poorly differentiated NET; high-grade neuroendocrine carcinoma; large cell neuroendocrine carcinoma, small cell carcinoma, or mixed small and large cell carcinoma.
Subjects currently receiving anti-cancer therapies (other than SSAs, which may continue).
Subjects who have received anti-cancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, immunotherapy, etc.).
Must not be experiencing a Grade 3 or 4 toxicity from previous anti-cancer treatment
Must not be receiving other anti-cancer therapies (except somatostatin analogues, which may be allowed)
Must not have poorly controlled diabetes mellitus, known central nervous system involvement by malignant disease or insufficient bone marrow, renal, or hepatic function
Clareo Health | A Study of XmAb®18087 in Subjects With NET and GIST
